The looming case is expected to be the most sweeping abortion issue the high court examines since overturning Roe v. Wade, with implications that extend far beyond reproductive health and could impact how a vast array of drugs are approved and regulated. Read more at Politico
If lower court rulings were left in place, they “would impose grave harms on the government, mifepristone’s sponsors, women seeking medication abortions, and the public,” Prelogar added. Among other things, access to the pill by mail — which the FDA formally approved in 2021 — would be curtailed. Read more at NBC News
While Texas can ban mifepristone, by what authority can it restrict its order and transportation through the U.S. Postal Service without challenging the way telemedicine works? The looming question for legislators: Is banning a single medication worth jeopardizing the convenient and cost-effective health care telemedicine provides for millions of Americans? Read more at The Hill … Read more
